product name Nobiletin
Description: Nobiletin, a citrus flavonoid isolated from citrus peels like in tangerine, which has anti-inflammatory and anti-tumor activities. Nobiletin has the ability to suppress tumor growth and metastasis. In human nasopharyngeal carcinoma cell lines (HONE-1 and NPC-BM), nobiletin treatment significantly inhibited cells invasion via inhibiting the phosphorylation of ERK1/2. When tested with rat C6 glioma cell, nobiletin was shown to inhibit cell proliferation via suppress ERK activity.
References: Cancer Res. 2000 Sep 15;60(18):5059-66; Cancer Res. 2002 Feb 15;62(4):1025-9.
402.39
Formula
C21H22O8
CAS No.
478-01-3
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 81 mg/mL (201.3 mM)
Water: <1 mg/mL
Ethanol: 3 mg/mL (7.5 mM)
Solubility (In vivo)
Synonyms
Hexamethoxyflavone
other peoduct :
| In Vitro |
In vitro activity: Nobiletin, a citrus flavonoid isolated from citrus peels like in tangerine, which has anti-inflammatory and anti-tumor activities. Nobiletin, a polymethoxyflavonoid, is identified as an inhibitor of both NO and O 2- generation. Nobiletin significantly inhibites two skin inflammation induced by double TPA application. It also suppresses the expression of cyclooxygenase-2 and inducible NO synthase proteins and prostaglandin E2 release. Nobiletin inhibites the tumor-invasive activity of human fibrosarcoma HT-1080 cells in the Matrigel model, not only by suppressing the expression of MMPs but also augmenting TIMP-1 production through interfering the phosphatidylinositol 3-kinase pathway (PI3-K). Nobiletin may also prevent atherosclerosis at the level of the vascular wall by inhibiting macrophage foam-cell formation. Kinase Assay: Cell Assay: Nobiletin is shown to have the ability to suppress tumor growth and metastasis. In human nasopharyngeal carcinoma cell lines (HONE-1 and NPC-BM), nobiletin treatment significantly inhibited cells invasion via inhibiting the phosphorylation of ERK1/2 [2]. When tested with rat C6 glioma cell, nobiletin was shown to inhibit cell proliferation via suppress ERK activity. |
|---|---|
| In Vivo | In mouse model with 5-min BCCAO-induced brain ischemia, treatment nobiletin (50 mg/kg) intraperitoneally for the consecutive 7 days significantly inhibited delayed neuronal death in the hippocampal CA1 neurons and improved contextual memory. In MPTP-induced Parkinson mouse model, administration of Nobiletin (50mg/kg i.p.) intraperitoneally for 2 consecutive weeks improved motor and cognitive deficits. |
| Animal model | Mouse |
| Formulation & Dosage | 50 mg/kg; i.p. injection |
| References | Cancer Res. 2000 Sep 15;60(18):5059-66; Cancer Res. 2002 Feb 15;62(4):1025-9. |
